{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:05:48Z","timestamp":1768838748900,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,9,3]],"date-time":"2011-09-03T00:00:00Z","timestamp":1315008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1208\/s12249-011-9682-2","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T13:14:59Z","timestamp":1315314899000},"page":"1136-1143","source":"Crossref","is-referenced-by-count":36,"title":["Nitrendipine Nanocrystals: Its Preparation, Characterization, and In Vitro\u2013In Vivo Evaluation"],"prefix":"10.1208","volume":"12","author":[{"given":"Peng","family":"Quan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengning","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongze","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinnong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fude","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,3]]},"reference":[{"issue":"3","key":"9682_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2125.1988.tb03318.x","volume":"25","author":"RA Prentis","year":"1988","unstructured":"Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964\u20131985). Br J Clin Pharmacol. 1988;25(3):387\u201396.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"9682_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413\u201320.","journal-title":"Pharm Res"},{"key":"9682_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cocis.2004.06.009","volume":"9","author":"AA Date","year":"2004","unstructured":"Date AA, Patravale VB. Current strategies for engineering drug nanoparticles. Curr Opin Colloid Interface Sci. 2004;9:222\u201335.","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"1\u20132","key":"9682_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijpharm.2007.12.016","volume":"355","author":"L Gao","year":"2008","unstructured":"Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm. 2008;355(1\u20132):321\u20137.","journal-title":"Int J Pharm"},{"issue":"9","key":"9682_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrd1494","volume":"3","author":"BE Rabinow","year":"2004","unstructured":"Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785\u201396.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"9682_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1211\/0022357023691","volume":"56","author":"VB Patravale","year":"2004","unstructured":"Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56(7):827\u201340.","journal-title":"J Pharm Pharmacol"},{"issue":"1\u20132","key":"9682_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijpharm.2004.07.019","volume":"284","author":"JE Kipp","year":"2004","unstructured":"Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284(1\u20132):109\u201322.","journal-title":"Int J Pharm"},{"issue":"6","key":"9682_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/jps.21563","volume":"98","author":"B Eerdenbrugh Van","year":"2009","unstructured":"Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Van Humbeeck J, Augustijns P, et al. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci. 2009;98(6):2091\u2013103.","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"9682_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ijpharm.2010.03.002","volume":"391","author":"J Pardeike","year":"2010","unstructured":"Pardeike J, Muller RH. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. Int J Pharm. 2010;391(1\u20132):322\u20139.","journal-title":"Int J Pharm"},{"issue":"21","key":"9682_CR10","doi-asserted-by":"publisher","first-page":"12481","DOI":"10.1021\/la9016432","volume":"25","author":"S Verma","year":"2009","unstructured":"Verma S, Huey BD, Burgess DJ. Scanning probe microscopy method for nanosuspension stabilizer selection. Langmuir. 2009;25(21):12481\u20137.","journal-title":"Langmuir"},{"issue":"7","key":"9682_CR11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/03639040802623941","volume":"35","author":"X Li","year":"2009","unstructured":"Li X, Gu L, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm. 2009;35(7):827\u201333.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1\u20132","key":"9682_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijpharm.2009.07.005","volume":"380","author":"S Verma","year":"2009","unstructured":"Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro\/nanosuspensions. Int J Pharm. 2009;380(1\u20132):216\u201322.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"9682_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijpharm.2010.07.044","volume":"399","author":"R Shegokar","year":"2010","unstructured":"Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399(1\u20132):129\u201339.","journal-title":"Int J Pharm"},{"issue":"2","key":"9682_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1014276917363","volume":"19","author":"C Jacobs","year":"2002","unstructured":"Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002;19(2):189\u201394.","journal-title":"Pharm Res"},{"issue":"3","key":"9682_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ejpb.2004.03.022","volume":"58","author":"J Moschwitzer","year":"2004","unstructured":"Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm. 2004;58(3):615\u20139.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"9682_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ijpharm.2007.08.036","volume":"350","author":"R Xiong","year":"2008","unstructured":"Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm. 2008;350(1\u20132):338\u201343.","journal-title":"Int J Pharm"},{"issue":"2","key":"9682_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0378-5173(99)00414-7","volume":"196","author":"KP Krause","year":"2000","unstructured":"Krause KP, Kayser O, Mader K, Gust R, Muller RH. Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int J Pharm. 2000;196(2):169\u201372.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"9682_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijpharm.2007.03.011","volume":"340","author":"MA Kassem","year":"2007","unstructured":"Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340(1\u20132):126\u201333.","journal-title":"Int J Pharm"},{"issue":"1","key":"9682_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejpb.2005.05.009","volume":"62","author":"CM Keck","year":"2006","unstructured":"Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62(1):3\u201316.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"9682_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijpharm.2008.12.030","volume":"371","author":"PR Mishra","year":"2009","unstructured":"Mishra PR, Al Shaal L, Muller RH, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm. 2009;371(1\u20132):182\u20139.","journal-title":"Int J Pharm"},{"issue":"1","key":"9682_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","volume":"47","author":"RH Muller","year":"2001","unstructured":"Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3\u201319.","journal-title":"Adv Drug Deliv Rev"},{"key":"9682_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0378-5173(97)00311-6","volume":"160","author":"RH Muller","year":"1998","unstructured":"Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm. 1998;160:229\u201337.","journal-title":"Int J Pharm"},{"issue":"1","key":"9682_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1248\/cpb.54.37","volume":"54","author":"L Wang","year":"2006","unstructured":"Wang L, Cui FD, Sunada H. Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method. Chem Pharm Bull. 2006;54(1):37\u201343.","journal-title":"Chem Pharm Bull"},{"issue":"1","key":"9682_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijpharm.2009.05.062","volume":"379","author":"X Pu","year":"2009","unstructured":"Pu X, Sun J, Wang Y, Liu X, Zhang P, Tang X, et al. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm. 2009;379(1):167\u201373.","journal-title":"Int J Pharm"},{"key":"9682_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1201\/9780203908280","volume-title":"Crystallization technology handbook","author":"A Mersmann","year":"2001","unstructured":"Mersmann A, Eble A, Heyer C. Crystal Growth. In: Mersmann A, editor. Crystallization technology handbook. 2nd ed. New York: Taylor & Francis; 2001. p. 102\u20139.","edition":"2"},{"issue":"11","key":"9682_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1252\/jcej.35.1219","volume":"35","author":"S Kaneko","year":"2002","unstructured":"Kaneko S, Yamagami Y, Tochihara H, Hirasawa I. Effect of Supersaturation on Crystal Size and Number of Crystals Produced in Antisolvent Crystallization. J Chem Eng Jpn. 2002;35(11):1219\u201323.","journal-title":"J Chem Eng Jpn"},{"issue":"1","key":"9682_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijpharm.2008.07.023","volume":"364","author":"B Eerdenbrugh Van","year":"2008","unstructured":"Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364(1):64\u201375.","journal-title":"Int J Pharm"},{"key":"9682_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11051-008-9357-4","volume":"10","author":"L Gao","year":"2008","unstructured":"Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res. 2008;10:845\u201362.","journal-title":"J Nanopart Res"},{"issue":"5","key":"9682_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/03639040600975147","volume":"33","author":"D Zhang","year":"2007","unstructured":"Zhang D, Tan T, Gao L, Zhao W, Wang P. Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies. Drug Dev Ind Pharm. 2007;33(5):569\u201375.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1\u20132","key":"9682_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijpharm.2007.11.062","volume":"354","author":"V Teeranachaideekul","year":"2008","unstructured":"Teeranachaideekul V, Junyaprasert V, Souto E, Muller R. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int J Pharm. 2008;354(1\u20132):227\u201334.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"9682_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijpharm.2006.01.008","volume":"312","author":"P Kocbek","year":"2006","unstructured":"Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm. 2006;312(1\u20132):179\u201386.","journal-title":"Int J Pharm"},{"key":"9682_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/30415","volume":"393","author":"M Schmidt","year":"1998","unstructured":"Schmidt M, Kusche R, Issendorff Bv, Haberland H. Irregular variations in themelting point of size-selected atomic clusters. Nature. 1998;393:238\u201340.","journal-title":"Nature"},{"issue":"1","key":"9682_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1103\/PhysRevLett.77.99","volume":"77","author":"SL Lai","year":"1996","unstructured":"Lai SL, Guo JY, Petrova V, Ramanath G, Allen LH. Size-Dependent Melting Properties of Small Tin Particles: Nanocalorimetric Measurements. Phys Rev Lett. 1996;77(1):99\u2013102.","journal-title":"Phys Rev Lett"},{"key":"9682_CR34","first-page":"35","volume-title":"Developing Solid Oral Dosage Forms","author":"GGZ Zhang","year":"2009","unstructured":"Zhang GGZ, Zhou D. Crystalline and Amorphous Solids. In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR, editors. Developing Solid Oral Dosage Forms. 1st ed. Oxford: Elsevier; 2009. p. 35\u20136.","edition":"1"},{"issue":"7","key":"9682_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.addr.2007.05.003","volume":"59","author":"F Kesisoglou","year":"2007","unstructured":"Kesisoglou F, Panmai S, Wu Y. Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631\u201344.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"9682_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0378-5173(89)90069-0","volume":"51","author":"RJ Hintz","year":"1989","unstructured":"Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm. 1989;51(1):9\u201317.","journal-title":"Int J Pharm"},{"issue":"3","key":"9682_CR37","first-page":"295","volume":"3","author":"JU Junghanns","year":"2008","unstructured":"Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295\u2013309.","journal-title":"Int J Nanomedicine"},{"issue":"10","key":"9682_CR38","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1081\/DDC-120025866","volume":"29","author":"HG Choi","year":"2003","unstructured":"Choi HG, Kim DD, Jun HW, Yoo BK, Yong CS. Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin. Drug Dev Ind Pharm. 2003;29(10):1085\u201394.","journal-title":"Drug Dev Ind Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-011-9682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-011-9682-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-011-9682-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-011-9682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T23:48:16Z","timestamp":1559605696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-011-9682-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,3]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9682"],"URL":"https:\/\/doi.org\/10.1208\/s12249-011-9682-2","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,3]]}}}